دورية أكاديمية
Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies.
| العنوان: | Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies. |
|---|---|
| المؤلفون: | Provenzano R; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., De Caro C; Department of Science of Health, Magna Græcia University, Catanzaro, Italy., Vitiello A; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., Izzo L; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., Ritieni A; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., Ungaro F; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., Quaglia F; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy., Russo E; Department of Science of Health, Magna Græcia University, Catanzaro, Italy., Miro A; Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy. miro@unina.it., d'Angelo I; DiSTABiF, University of Campania 'Luigi Vanvitelli', Via A. Vivaldi, 43, 81100, Caserta, Italy. |
| المصدر: | Drug delivery and translational research [Drug Deliv Transl Res] 2024 Jun; Vol. 14 (6), pp. 1648-1659. Date of Electronic Publication: 2023 Dec 08. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Springer |
| مواضيع طبية MeSH: | Emulsions* , Mouth Mucosa*/metabolism , Cannabidiol*/administration & dosage , Cannabidiol*/pharmacokinetics , Cannabidiol*/chemistry , Surface-Active Agents*/chemistry, Animals ; Administration, Buccal ; Nanoparticles/chemistry ; Nanoparticles/administration & dosage ; Triglycerides/chemistry ; Triglycerides/administration & dosage ; Triglycerides/pharmacokinetics ; Biological Availability ; Male ; Polysorbates/chemistry ; Glycerides/chemistry ; Mice ; Solubility ; Drug Liberation ; Drug Delivery Systems |
| مستخلص: | Cannabidiol (CBD) has gained significant attention as a complementary and alternative medicine due to its promising therapeutic properties. However, CBD faces obstacles when administered orally due to its poor solubility in water, leading to limited absorption into the bloodstream and low and variable bioavailability. Therefore, the development of innovative delivery approaches that can enhance CBD's bioavailability, facilitate administration, and promote patient adherence is crucial. We propose a new approach for buccal delivery of CBD based on a self-assembling nanoemulsion (NE) made of a mixture of surfactants (Tween 80 and Labrasol) and medium chain triglycerides (MCTs). The NE formulation showed properties suitable for buccal administration, including appropriate size, CBD content, and surface properties, and, if compared to a CBD-MCT solution, it exhibited better control of administered doses, faster dissolution in buccal medium, and enhanced stability. The CBD-NE effectively released its active load within 5 h, remained stable even when diluted in simulated buccal fluids, and could be easily administered through a commercially available spray, providing consistent and reproducible doses of NE with optimized properties. In vitro permeation studies demonstrated that the CBD-NE facilitated swift and consistent permeation through the buccal mucosa, resulting in a higher concentration in the acceptor compartment compared to CBD-MCT. Furthermore, the in vivo study in mice showed that a single buccal administration of CBD-NE led to a quicker onset of action than a CBD solution in MCT, while maintaining the same plasma levels over time and leading to typically higher plasma concentrations compared to those usually achieved through oral administration. In conclusion, our CBD-NE represents a promising alternative formulation strategy for buccal CBD administration, overcoming the challenges associated with conventional formulations such as variable bioavailability and low control of administered doses. (© 2023. Controlled Release Society.) |
| References: | De Caro C, Leo A, Citraro R, De Sarro C, Russo R, Calignano A, et al. The potential role of cannabinoids in epilepsy treatment. Expert Rev Neurother. 2017;17:1069–79. (PMID: 10.1080/14737175.2017.137301928845714) Yau GTY, Tai W, Arnold JC, Chan HK, Kwok PCL. Cannabidiol for the treatment of brain disorders: Therapeutic potential and routes of administration. Pharm Res [Internet]. 2023; Available from: https://doi.org/10.1007/s11095-023-03469-1 . Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20. (PMID: 10.1056/NEJMoa161161828538134) Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–97. (PMID: 10.1056/NEJMoa171463129768152) Iannone LF, Arena G, Battaglia D, Bisulli F, Bonanni P, Boni A, et al. Results from an Italian expanded access program on cannabidiol treatment in highly refractory Dravet syndrome and Lennox-Gastaut syndrome. Front Neurol. 2021;12:1–9. (PMID: 10.3389/fneur.2021.673135) Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162:153–61. Available from: https://doi.org/10.1016/j.schres.2015.01.033 . García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10:1–34. (PMID: 10.3390/biom10111575) Tomer S, Mu W, Suryawanshi G, Ng H, Wang L, Wennerberg W, et al. Cannabidiol modulates expression of type I IFN response genes and HIV infection in macrophages. Front Immunol. 2022;13:1–13. (PMID: 10.3389/fimmu.2022.926696) Lowe H, Toyang N, McLaughlin W. Potential of cannabidiol for the treatment of viral hepatitis. Pharmacognosy Res. 2017;9:116–8. (PMID: 10.4103/0974-8490.199780282506645330095) Salles ÉL, Khodadadi H, Jarrahi A, Ahluwalia M, Paffaro VA, Costigliola V, et al. Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. J Cell Mol Med. 2020;24:12869–72. (PMID: 10.1111/jcmm.15883330584257686987) Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022;8. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27. (PMID: 10.1016/j.tips.2009.07.00619729208) Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34:795–800. Available from: https://doi.org/10.1007/s40263-020-00741-5 . Contin M, Mohamed S, Santucci M, Lodi MAM, Russo E, Mecarelli O, et al. Cannabidiol in pharmacoresistant epilepsy: Clinical pharmacokinetic data from an expanded access program. Front Pharmacol. 2021;12:1–7. (PMID: 10.3389/fphar.2021.637801) Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9. Lattanzi S, Zaccara G, Russo E, La Neve A, Lodi MAM, Striano P. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Expert Rev Neurother. 2021;21:99–110. Available from: https://doi.org/10.1080/14737175.2021.1834383 . Ramalho ÍM de M, Pereira DT, Galvão GBL, Freire DT, Amaral-Machado L, Alencar É do N, et al. Current trends on cannabidiol delivery systems: Where are we and where are we going? Expert Opin. Drug Deliv. Taylor and Francis Ltd. 2021;1577–87. Reddy TS, Zomer R, Mantri N. Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phyther Res. 2023;1–13. De Prá MAA, Vardanega R, Loss CG. Lipid-based formulations to increase cannabidiol bioavailability: In vitro digestion tests, pre-clinical assessment and clinical trial. Int J Pharm. 2021;609. Kok LY, Bannigan P, Sanaee F, Evans JC, Dunne M, Regenold M, et al. Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. Eur J Pharm Sci. 2022;168:106058. Available from: https://doi.org/10.1016/j.ejps.2021.106058 . Wang C, Dong C, Lu Y, Freeman K, Wang C, Guo M. Digestion behavior, in vitro and in vivo bioavailability of cannabidiol in emulsions stabilized by whey protein-maltodextrin conjugate: Impact of carrier oil. Colloids Surfaces B Biointerfaces. 2023;223:113154. Available from: https://doi.org/10.1016/j.colsurfb.2023.113154 . Izgelov D, Shmoeli E, Domb AJ, Hoffman A. The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats. Int J Pharm. 2020;580:119201. Available from: https://doi.org/10.1016/j.ijpharm.2020.119201 . Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017;266:1–7. (PMID: 10.1016/j.jconrel.2017.09.01128890215) Itin C, Barasch D, Domb AJ, Hoffman A. Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. Int J Pharm. 2020;581. Crowley K, de Vries ST, Moreno-Sanz G. Self-reported effectiveness and safety of Trokie ® Lozenges: A standardized formulation for the buccal delivery of cannabis extracts. Front Neurosci. 2018;12. Huestis MA. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007. p. 1770–804. d’Angelo I, Provenzano R, Florio E, Lombardi A, Trama U, Ungaro F, et al. Transmucosal delivery of the medical Cannabis oil via a nanoemulsion formulation. J Drug Deliv Sci Technol. 2023;79:104004. Available from: https://doi.org/10.1016/j.jddst.2022.104004 . Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 2016;128:201–9. (PMID: 10.1016/j.jpba.2016.05.03327268223) Roger K, Cabane B. Why are hydrophobic/water interfaces negatively charged? Angew Chemie - Int Ed. 2012;51:5625–8. (PMID: 10.1002/anie.201108228) Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. Nanoemulsions: formation, structure, and physical properties. J Phys Condens Matter. 2006;18:R635–66. (PMID: 10.1088/0953-8984/18/41/R01) Tonoyan L, Babu D, Reiz B, Le T, Siraki AG. Heating of consumer cannabis oils can lead to free radical initiated degradation, causing CBD and THC depletion. Free Radic Biol Med. 2022;192:77–83. Available from: https://doi.org/10.1016/j.freeradbiomed.2022.09.005 . Nakano Y, Tajima M, Sugiyama E, Sato VH, Sato H. Development of a novel nano-emulsion formulation to improve intestinal absorption of cannabidiol. Med Cannabis Cannabinoids. 2019;2:35–42. (PMID: 10.1159/000497361346763328489317) Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017;27:1223–37. (PMID: 10.1016/j.euroneuro.2017.10.03729129557) della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, et al. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2023;9. |
| فهرسة مساهمة: | Keywords: Buccal delivery; CBD bioavailability; CBD nanoemulsion |
| المشرفين على المادة: | 0 (Emulsions) 19GBJ60SN5 (Cannabidiol) 0 (Surface-Active Agents) 0 (Triglycerides) 00BT03FSO2 (Labrasol) 0 (Polysorbates) 0 (Glycerides) |
| تواريخ الأحداث: | Date Created: 20231208 Date Completed: 20240426 Latest Revision: 20240426 |
| رمز التحديث: | 20240427 |
| DOI: | 10.1007/s13346-023-01481-x |
| PMID: | 38064145 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2190-3948 |
|---|---|
| DOI: | 10.1007/s13346-023-01481-x |